Ozempic users generally see a weight loss of around 6% to 10% of their body weight in similar diabetes trials (though higher doses used in Wegovy trials show up to 15%)
A blended vial that co-formulates CJC-1295 (in the no DAC form) with Ipamorelin exists because researchers modeling growth-hormone (GH) physiology have long been interested in a specific idea: that two secretagogues acting on two different pituitary receptors produce a larger, cleaner GH pulse than either compound alone
Abrams SL, Evangelisi C, Chiarini F, Misaghian N, Basecke J, Millela M, Tafuri A, Libra M, Stivala F, Konopleva M, Andreeff M , Steelman LS, Troppmair J, Martelli AM, McCubrey JA
Everyones likelihood of risks and benefits is highly individualized, but these medications can touch on very personal issues, like weight status, weight stigma, body image, chronic illness management, and future disease risk, which must be carefully considered and handled with compassion plus a focus on currently available scientific evidence